Torrent Pharmaceuticals posted a steady set of numbers in the fourth quarter, reinforcing confidence in its growth trajectory ...

Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

Mumbai: Torrent Pharmaceuticals on Wednesday reported a 0.99 per cent quarter-on-quarter (QoQ) decline in its net profit for ...

With the stock's price at Rs 3222.50, Torrent Pharmaceuticals' performance reflects its position in the pharmaceutical sector.

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

Torrent Pharmaceuticals reported steady growth in Q4 with an 11% rise in profit and strong margins. The board recommended a ...

Torrent Pharmaceuticals reports strong revenue growth in key markets, posting a 15.4% rise in net profit for FY 2024-25.

The drugmaker, part of the ₹45,000-crore Torrent Group, also announced a leadership transition. As part of a long-term ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Indian drugmaker Torrent Pharmaceuticals missed fourth-quarter profit and revenue estimates on Tuesday, hurt by currency depreciation in Brazil, its top overseas market by revenue.

Jefferies recommends Buy on DLF, CMS Info Systems, and Torrent Pharma, citing strong fundamentals and growth prospects. Check ...

Torrent Pharmaceuticals added 1.53% to Rs 3,292.95 after the company's consolidated net profit increased 10.91% to Rs 498 crore in Q4 FY25 as against Rs 449 crore posted in Q4 FY24.